Search - tctmd.com

Displaying 301 - 320 of 455

Sort: Relevancy | Date

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

Michael O'Riordan

March 02, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Caitlin E. Cox

December 05, 2017

Top Stories in Cardiology, November 2017

Podcast Heart Sounds

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

Advertisement

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

TCTMD’s Top 10 Most Popular Stories for January 2018

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Top Stories in Cardiology, November 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Evolocumab Not Cost-Effective at Current List Price

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content